需要机械通气的重度免疫抑制COVID-19患者中COVID-19相关肺曲霉病的高负担
这项回顾性单中心观察研究纳入2020年3月1日至2022年11月14日鲁汶大学医院ICU的335例需机械通气的重症COVID-19成人患者,按2020年ECMM/ISHAM标准诊断CAPA。CAPA总发生率为33%(112/335),EORTC/MSGERC宿主因素阳性者为62%(50/81)vs 阴性者24%(62/254);疫苗接种时代CAPA发生率从24%(57/241)升至59%(55/94)。
要点
- 335例需机械通气的重症COVID-19患者中,CAPA发生率为33%(112/335)。
- EORTC/MSGERC宿主因素阳性者CAPA发生率62%(50/81)vs 阴性者24%(62/254)。
- 疫苗接种时代CAPA发生率59%(55/94)vs 疫苗接种前24%(57/241)。
核心结论
- EORTC/MSGERC侵袭性霉菌病宿主因素与CAPA发生率升高及更差结局相关,是疫苗接种时代CAPA发生率显著升高的主要驱动因素。
- 作者认为研究结果 warrant 对重症COVID-19患者进行抗真菌预防的进一步研究。
研究设计与样本
- 回顾性、单中心、观察性研究,纳入2020年3月1日至2022年11月14日鲁汶大学医院ICU收治的335例需机械通气的重症COVID-19成人患者。
- 按2020年ECMM/ISHAM标准诊断 probable 或 proven CAPA。
主要发现
- 335例患者中,300例(90%)行支气管肺泡灌洗采样,112例(33%)诊断为CAPA。
- EORTC/MSGERC宿主因素阳性患者CAPA发生率为62%(50/81),阴性患者为24%(62/254)。
- 疫苗接种时代CAPA发生率从2021年10月前入ICU患者的24%(57/241)升至此后入ICU患者的59%(55/94)。
- EORTC/MSGERC宿主因素和疫苗接种时代入ICU均与CAPA发生独立相关。
- 在疫苗接种时代,CAPA仍为与死亡风险相关的独立危险因素。
关键数值与推荐
- CAPA诊断依据2020年ECMM/ISHAM标准(probable 或 proven CAPA)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a frequent superinfection in critically ill patients with COVID-19 and is associated with increased mortality rates. The increasing proportion of severely immunocompromised patients with COVID-19 who require mechanical ventilation warrants research into the incidence and impact of CAPA during the vaccination era. METHODS: We performed a retrospective, monocentric, observational study. We collected data from adult patients with severe COVID-19 requiring mechanical ventilation who were admitted to the intensive care unit (ICU) of University Hospitals Leuven, a tertiary referral center, between 1 March 2020 and 14 November 2022. Probable or proven CAPA was diagnosed according to the 2020 European Confederation for Medical Mycology/International Society for Human and Animal Mycology (ECMM/ISHAM) criteria. RESULTS: We included 335 patients. Bronchoalveolar lavage sampling was performed in 300 (90%), and CAPA was diagnosed in 112 (33%). The incidence of CAPA was 62% (50 of 81 patients) in European Organisation for Research and Treatment of Cancer (EORTC)/Mycosis Study Group Education and Research Consortium (MSGERC) host factor-positive patients, compared with 24% (62 of 254) in host factor-negative patients. The incidence of CAPA was significantly higher in the vaccination era, increasing from 24% (57 of 241) in patients admitted to the ICU before October 2021 to 59% (55 of 94) in those admitted since then. Both EORTC/MSGERC host factors and ICU admission in the vaccination era were independently associated with CAPA development. CAPA remained an independent risk factor associated with mortality risk during the vaccination era. CONCLUSIONS: The presence of EORTC/MSGERC host factors for invasive mold disease is associated with increased CAPA incidence and worse outcome parameters, and it is the main driver for the significantly higher incidence of CAPA in the vaccination era. Our findings warrant investigation of antifungal prophylaxis in critically ill patients with COVID-19.
引用
- Feys S, Lagrou K, Lauwers HM, et al. High Burden of COVID-19-Associated Pulmonary Aspergillosis in Severely Immunocompromised Patients Requiring Mechanical Ventilation. Clin Infect Dis. 2024. PMID: 37691392. doi:10.1093/cid/ciad546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。